[go: up one dir, main page]

CO5150183A1 - THE INHIBITION OF VASCULAR HYPERPERMEABILITY FORMATION - Google Patents

THE INHIBITION OF VASCULAR HYPERPERMEABILITY FORMATION

Info

Publication number
CO5150183A1
CO5150183A1 CO99070343A CO99070343A CO5150183A1 CO 5150183 A1 CO5150183 A1 CO 5150183A1 CO 99070343 A CO99070343 A CO 99070343A CO 99070343 A CO99070343 A CO 99070343A CO 5150183 A1 CO5150183 A1 CO 5150183A1
Authority
CO
Colombia
Prior art keywords
kdr
inhibition
signaling function
receptor
cell signaling
Prior art date
Application number
CO99070343A
Other languages
Spanish (es)
Inventor
Lee D Arnold
Peter F Bousquet
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of CO5150183A1 publication Critical patent/CO5150183A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)

Abstract

Un método de inhibición de la hiperpermeabilidad vascular en un individuo caracterizado por comprender la inhibición de la función de señalización del KDR.El método de la Reivindicación 1 caracterizado porque dicha inhibición de la función de señalización celular del KDR es selectiva para este receptor.El método de la Reivindicación 1 caracterizado porque dicha función de señalización celular del KDR es estimulada por la unión de un ligando de activación a la porción receptora del KDR.El método de la Reivindicación 3 caracterizado porque dicha inhibición de la función de señalización celular del KDR es selectiva para este receptor.El método de la Reivindicación 1 caracterizado porque dicha inhibición de la función de señalización celular del KDR es un proceso seleccionado del grupo integrado por el bloqueo de la producción del ligando de activación, la modulación de la unión del ligando de activación al receptor KDR tirosina quinasa, la interrupción de la dimerización del receptor, el bloqueo de la transfosforilación, la inhibición de la actividad del KDR, el deterioro del suministro de substratos intracelulares de KDR, y la interrupción de la señalización descendente iniciada por la actividad de fosforilación del KDR tirosina quinasa.El método de la Reivindicación 5 caracterizado porque dicha inhibición de la función de señalización celular del KDR es selectiva para este receptor.El método de la Reivindicación 1 caracterizado porque dicha inhibición se produce mediante la administración de un compuesto a dicho individuo.A method of inhibiting vascular hyperpermeability in an individual characterized by comprising the inhibition of the KDR signaling function. The method of Claim 1 characterized in that said inhibition of the KDR cell signaling function is selective for this receptor. of Claim 1 characterized in that said KDR cell signaling function is stimulated by the binding of an activation ligand to the KDR receptor portion.The method of Claim 3 characterized in that said inhibition of the KDR cell signaling function is selective for this receiver. The method of Claim 1 characterized in that said inhibition of the cell signaling function of KDR is a process selected from the group consisting of blocking the production of the activation ligand, modulation of the binding of the activation ligand to the KDR receptor tyrosine kinase, interrupted n of dimerization of the receptor, blocking of transfosphorylation, inhibition of KDR activity, deterioration of the supply of intracellular substrates of KDR, and disruption of downstream signaling initiated by phosphorylation activity of KDR tyrosine kinase. The method of Claim 5 characterized in that said inhibition of the cellular signaling function of KDR is selective for this receptor.The method of Claim 1 characterized in that said inhibition is produced by administering a compound to said individual.

CO99070343A 1998-11-06 1999-11-08 THE INHIBITION OF VASCULAR HYPERPERMEABILITY FORMATION CO5150183A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10746298P 1998-11-06 1998-11-06

Publications (1)

Publication Number Publication Date
CO5150183A1 true CO5150183A1 (en) 2002-04-29

Family

ID=22316735

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99070343A CO5150183A1 (en) 1998-11-06 1999-11-08 THE INHIBITION OF VASCULAR HYPERPERMEABILITY FORMATION

Country Status (19)

Country Link
EP (1) EP1126842A2 (en)
JP (1) JP2002529421A (en)
KR (1) KR20010080952A (en)
CN (1) CN1342077A (en)
AR (1) AR023912A1 (en)
AU (1) AU1908000A (en)
BG (1) BG105476A (en)
BR (1) BR9915139A (en)
CA (1) CA2347916A1 (en)
CO (1) CO5150183A1 (en)
CZ (1) CZ20011564A3 (en)
HU (1) HUP0104302A3 (en)
ID (1) ID29063A (en)
IL (1) IL142583A0 (en)
NO (1) NO20012218L (en)
PL (1) PL348163A1 (en)
SK (1) SK5052001A3 (en)
TR (1) TR200102278T2 (en)
WO (1) WO2000027414A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2016953A3 (en) 1998-12-22 2009-04-15 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
IL144144A0 (en) 1999-01-13 2002-05-23 Bayer Ag Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CZ304320B6 (en) * 1999-12-22 2014-03-05 The Scripps Research Institute Pharmaceutical composition containing tyrosine kinase Src and Yes proteins along with a pharmaceutically acceptable carrier and article of manufacture
DE10021246A1 (en) * 2000-04-25 2001-10-31 Schering Ag New N-substituted benzamide derivatives are tyrosine kinase KDR and FLT inhibitors useful e.g. for treating tumors, psoriasis, rheumatoid arthritis, diabetic retinopathy or liver sclerosis
US20040242545A1 (en) * 2001-07-26 2004-12-02 Santen Phamaceutical Co., Ltd. Remedy for glaucoma comprising as the active ingredient compound having p13 kinase inhibitory effect
DK1478358T3 (en) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylate for the treatment of diseases characterized by abnormal angiogenesis
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
EP1587944A4 (en) 2002-03-01 2007-03-21 Dyax Corp Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
WO2004045543A2 (en) * 2002-11-14 2004-06-03 Dharmacon, Inc. Functional and hyperfunctional sirna
ES2557286T3 (en) 2003-03-03 2016-01-25 Dyax Corp. Uses of peptides that specifically bind to the HGF receptor (cMet)
DE602004011340T2 (en) 2003-05-20 2008-11-06 Bayer Healthcare Llc DIARYL-UREA SUBSTANCES WITH CHINESE-INHIBITING EFFECT
CL2004001834A1 (en) 2003-07-23 2005-06-03 Bayer Pharmaceuticals Corp COMPOUND 4- {4- [3- (4-CHLORO-3-TRIFLUOROMETILFENIL) -UREIDO] -3-FLUOROFENOXI} -PIRIDIN-2-METHYLAMIDE, RAF INHIBITOR, VEGFR, P38 AND PDGFR KINASES, ITS SALTS; PHARMACEUTICAL COMPOSIICON; PHARMACEUTICAL COMBINATION; AND ITS USE TO TREAT HYPERPROL DISORDERS
CA2669832A1 (en) * 2006-11-15 2008-05-22 Coda Therapeutics, Inc. Improved methods and compositions for wound healing
EP2598639A4 (en) 2010-07-28 2014-08-13 Alcon Res Ltd VEGFA TARGETING SIARN AND IN VIVO TREATMENT METHODS
JP6683686B2 (en) 2014-08-22 2020-04-22 オークランド ユニサービシーズ リミティド Channel regulator
CN106381330A (en) * 2016-08-30 2017-02-08 张建华 Primer and kit for detecting susceptibility of communicating hydrocephalus
WO2019182333A1 (en) * 2018-03-19 2019-09-26 주식회사 파멥신 Anti-vegfr-2 antibody
CN109718253B (en) * 2019-01-16 2021-09-24 中国人民解放军总医院 Use of a bacterium that metabolizes histamine in preventing or treating altitude sickness

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE789948A (en) * 1971-10-13 1973-04-11 Sandoz Sa NEW DERIVATIVES OF PYRAZOLE, THEIR PREPARATION AND THEIR APPLICATION AS MEDICINAL PRODUCTS
US3843664A (en) * 1973-02-20 1974-10-22 Sandoz Ag Substituted naphtho pyrazoles
US3843665A (en) * 1973-04-11 1974-10-22 Sandoz Ag Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
US3843666A (en) * 1973-05-29 1974-10-22 Sandoz Ag Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
WO1998033917A1 (en) * 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
US6346398B1 (en) * 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
FR2742662B1 (en) * 1995-12-21 1998-01-23 Centre Nat Rech Scient ANTI-IDIOTYPIC ANTIBODIES OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND THEIR USE AS MEDICAMENTS
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
DE19638745C2 (en) * 1996-09-11 2001-05-10 Schering Ag Monoclonal antibodies against the extracellular domain of the human VEGF receptor protein (KDR)
US6204011B1 (en) * 1997-06-18 2001-03-20 Merck & Co., Inc. Human receptor tyrosine kinase, KDR
CA2304466A1 (en) * 1997-10-06 1999-04-15 Basf Aktiengesellschaft Indeno[1,2-c]pyrazole derivatives for inhibiting tyrosine kinase activity
WO1999017769A1 (en) * 1997-10-06 1999-04-15 Basf Aktiengesellschaft INDENO[1,2-c]-, NAPHTHO[1,2-c]- AND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLE DERIVATIVES
JP2002512962A (en) * 1998-04-30 2002-05-08 ビーエーエスエフ アクチェンゲゼルシャフト Substituted tricyclic pyrazole derivatives having protein kinase activity

Also Published As

Publication number Publication date
SK5052001A3 (en) 2002-10-08
ID29063A (en) 2001-07-26
BR9915139A (en) 2001-08-07
TR200102278T2 (en) 2001-12-21
NO20012218L (en) 2001-06-18
KR20010080952A (en) 2001-08-25
WO2000027414A3 (en) 2000-09-08
AR023912A1 (en) 2002-09-04
NO20012218D0 (en) 2001-05-04
PL348163A1 (en) 2002-05-06
IL142583A0 (en) 2002-03-10
CA2347916A1 (en) 2000-05-18
BG105476A (en) 2002-02-28
AU1908000A (en) 2000-05-29
CZ20011564A3 (en) 2002-04-17
HUP0104302A3 (en) 2002-11-28
HUP0104302A2 (en) 2002-03-28
EP1126842A2 (en) 2001-08-29
JP2002529421A (en) 2002-09-10
WO2000027414A2 (en) 2000-05-18
CN1342077A (en) 2002-03-27

Similar Documents

Publication Publication Date Title
CO5150183A1 (en) THE INHIBITION OF VASCULAR HYPERPERMEABILITY FORMATION
GR20010300033T1 (en) Raf kinase inhibitors
PL343083A1 (en) Inhibition of raf kinase using substituted heterocyclic ureas
MD1616G2 (en) Tricyclic compounds and method of inhibiting the tyrasin kinases receptors of the epidermal growth factor, pharmaceutical composition, methods of preventing the blastocites implantation and mammals treatment
ATE238771T1 (en) PROCESS FOR PRODUCTION OF SOLUBLE DISTRIBUTION SYSTEMS USING VOLATILE SALTS
DK0556310T3 (en) Quinazoline derivatives to increase antitumor activity
MY128370A (en) Pyrrolotriazane inhibitors of kinases
ATE39127T1 (en) SOLID DETERGENTS AND DISHWASHING PROCEDURES WHEN USING SOLID DETERGENTS.
WO2000069429A3 (en) Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
PL365637A1 (en) Quinazoline ditosylate salt compounds
AP1553A (en) Tricyclic inhibitors of poly (ADP-Ribose) polymerases.
AU5482601A (en) Effervescent granules and methods for their preparation
GEP20053660B (en) Novel Tyrosine Kinase Inhibitors
MXPA99000214A (en) Tricyclic benzazepine vasopressin antagonists.
ES2164157T3 (en) MONOCICLOPENTADIENILO-METAL COMPOUNDS FOR ETHYLENE-ALFA-OLEFINE COPOLYMER PRODUCTION CATALYSTS.
DE69332714D1 (en) DNA LINKS WITH MANNURONAN C-5 EPIMERASE-ENCODING SEQUENCES
ATE423110T1 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING CELLULAR PROLIFERATIVE DISEASES
DE69333413D1 (en) 5-HT2 ANTAGONISTS IN TREATING VENOUS STATES
TR200002646T2 (en) New eprosartan compositions
DE69912743D1 (en) TREATMENT OF FOLLICULAR LYMPHOMAS USING INHIBITORS OF THE LYMPHOTOXIN (LT) ACTIVATION WAY
ES2053061T3 (en) AMINOBUTANOL DERIVATIVE AND PROCEDURE FOR THE PREPARATION OF 3-PIRROLIDINOL FROM THIS DERIVATIVE.
DE60041399D1 (en) Inhibitors of protein-dependent cation channels and their use in the treatment of ischemic-related diseases
ATE414700T1 (en) METHOD FOR PRODUCING 6-Ä(4,5-DIHYDRO-1H-IMIDAZOL-2-YL)AMINO-Ü-7-METHYL-1H-BENZIMIDAZOLE- - CARBONITRILES AND THEIR PREFERRED SALT FORM
YU84101A (en) Multi-stage method for producing gas-filled microcapsules
ATE235899T1 (en) NEW THERAPEUTIC USE OF COMPOUNDS WITH BETA-3 AGONISTIC ACTIVITY